

**Children's Hospital Of Eastern Ontario**

**MASTER FORMULA SHEET – NON-STERILE MANUFACTURING**

**PRODUCT:** RIFAMPIN 25 mg/mL SUSPENSION

**Date Prepared:** \_\_\_\_\_

**FINAL PRODUCT CHECKED BY:** \_\_\_\_\_

**EXPIRY DATE:** \_\_\_\_\_

INGREDIENT	MANUFACTURER	LOT #	MAN. EXPIRY DATE	FORMULA QUANTITY	QUANTITY USED	MFG BY	CHK BY
Rifampin 300 mg capsule				10 capsules			
Ora-Blend	Paddock labs			qs to 120 mL			

**EQUIPMENT**

- Mortar and pestle
- Graduated cylinder

**MANUFACTURING DIRECTIONS**

1. Empty contents of capsule in mortar and triturate into a fine powder.
2. Levigate powder with a small amount of vehicle to make a fine paste.
3. Continue to add vehicle by geometric dilution, until product is liquid enough to transfer to a graduated cylinder.
4. Rinse mortar several times with vehicle and add to product in graduated cylinder.
5. QS to final volume with vehicle.
6. Dispense in amber plastic bottles.

**Final Appearance**

Slightly granular, red-brown suspension.

**Master Sheet Revision Dates:** Aug 89; 22 Apr 96; aug 2018

**SAMPLE LABEL**

<p><b>RIFAMPIN 10 mg/mL Suspension</b>                  Shake well. Refrigerate/Room Temperature                  Date Prepared: _____ Date Expired: _____</p>
--

**STABILITY**

28 days at room temperature or in fridge.

**REFERENCE(S)**

- Taketomo CK, Hodding JH, Kraus DM, Pediatric Dosage Handbook, 12<sup>th</sup> Ed. 2005, pp 1109-1111
- Allen, Erickson. Stability of bethenachol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline HCL in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1998; 55:1386-8.
- Cross-references with HSC and IWK formulations, accessed Aug 2018

The non-sterile manufacturing formulas are provided for informational purposes for qualified health care professionals. The hospital will not assume responsibility for the continued currency of the information, any errors or omissions, and/or any consequences arising from the use of the information outside of CHEO.